We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
Add this topic to your myFT Digest for news straight to your inbox
Head of national infectious disease institute says he will leave post by January 2025
Omicron has exposed the weakness in current vaccines and revived interest in an all-protective ‘super jab’
The infectious diseases expert is a lightning rod in a politicised debate over the origins of Covid-19
Biden adviser calls for help on solving question of whether Covid ‘leaked’ from facility
‘Gain of function’ experiments that make viruses more deadly should be more tightly controlled, say some scientists
Recommendation to halt use of one-dose jab in US risks stoking hesitancy towards other shots
Regulators on both sides of Atlantic set to decide on approval in coming weeks
World’s largest healthcare company hopes to catch rivals working on two-jab products
Move comes as FDA gives emergency authorisation for use of plasma from recovered patients
Hollywood-style messages from politicians about beating the pandemic downplay the technical complexity
US-run trial of Gilead coronavirus therapy demonstrates ‘significant positive effect’
Thousands volunteer for tests of experimental ‘Ad26 mosaic’
Proponents say vaccines made of RNA and DNA will prove safer and cheaper
Industry response contrasts with slow reaction to previous disease outbreaks, including Ebola
Infectious Diseases chief calls for international debate
International Edition
